Cantargia
3,802 SEK -4,47%1.322 investorer følger denne virksomhed
Cantargia is a pharmaceutical company. Today, there is specialization in the development of antibody drugs used in the treatment of leukemia and other cancers such as lung and pancreatic cancer. The company's objective is to develop, sell and license drug candidates to companies operating in the mentioned work area. The largest operations are in the Nordic market, with headquarters in Lund.
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
NASDAQ Stockholm
CANTA
Daglig lav / høj pris
3,764 / 4,05
SEK
Markedsværdi
698,38 mio. SEK
Aktieomsætning
1,34 mio. SEK
Volumen
345 t
Seneste videoer
Finanskalender
Delårsrapport
21.05.2024
Generalforsamling
23.05.2024
Delårsrapport
28.08.2024
Delårsrapport
15.11.2024
Årsrapport
21.02.2025
Større aktionærerKilde: Millistream Market Data AB
Ejer | Kapital | Stemmer |
---|---|---|
Fjärde AP-fonden | 9,9 % | 9,9 % |
Första AP-Fonden | 7,1 % | 7,1 % |
Premium
This content is for our Premium customers only.
ViserAlle indholdstyper
Notice of annual general meeting in Cantargia AB (publ)
Cantargia publishes new data on the CAN10 antibody, detailing its interaction with IL1RAP and functional inhibition
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools